Pramlintide: what the evidence shows

What the human research shows

Small, real, and historically important: the proof that the amylin pathway works in people, twenty years before CagriSema. Three injections a day with meals is why almost nobody used it.

Evidence profile0–5

Metabolic & weightA2.3
Cardiovascular—0.0
Muscle & growth—0.0
Healing & repair—0.0
Neuro & sleep—0.0
Immune & inflammation—0.0
Sexual & hormonal—0.0
Skin & appearance—0.0
Ageing & longevity—0.0

Each score is confidence × effect size, taken from the best-evidenced benefit in that domain: the grade (A–D) sets the confidence, the measured effect sets the size. Hover a domain to see the outcomes behind it. Adverse effects are excluded and listed separately below.

Outcome	Grade	Effect size	Human studies	Where the evidence comes from
Blood glucose (with insulin)	AEstablished	Small	Approval programme (type 1 and type 2)	Modest HbA1c reductions of a few tenths of a point when added to insulin, with lower post-meal glucose excursions; the licensed indication.2
Body weight (obesity without diabetes)	BProbable	Moderate	1 RCT (n=411) with 8-month extension	Three-times-daily and higher twice-daily doses produced 3 kg more loss than placebo at four months and 6–7 kg at twelve, with placebo regaining and pramlintide maintaining. Never pursued to approval for obesity.1
Body weight (diabetes, with insulin)	AEstablished	Small	Approval programme	One to two kilograms less than insulin alone — meaningful because insulin usually adds weight.2
Adverse effectsadverse	AEstablished	Moderate	Same trials	Nausea in a large minority early on, fading with time; and, when combined with insulin, a risk of severe hypoglycaemia that carries a boxed warning in the US label.1 2

AMultiple good human trials, consistentBSome human trials, mostly consistentCFew or weak human studiesDAnimal or anecdotal onlyeffect size · red = adverse

Literature searched to 10 September 2026. Human studies only; animal and cell work informs the mechanism section and nothing else.

Registered trials

ClinicalTrials.gov lists 55 interventional studies naming Pramlintide as an intervention — 39 completed, 1 recruiting, and 13 with results posted to the registry.

A registration is not a result. Anyone can register a study, and many never report — so this list shows what has been attempted, not what has been shown. The graded evidence above is the answer to whether something works.

Study	Phase	Status	Participants	Sponsor	Results
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 DiabetesNCT00467649 · started May 2007	Phase 4	Completed	112	AstraZeneca	Posted
Use of Exenatide and Pramlintide to Decrease Post-prandial HyperglycemiaNCT01269047 · started Aug 2009	Phase 4	Completed	37	Albert Einstein College of Medicine	Posted
Demonstrate the Effects of Pramlintide on Weight Reduction in SchizophreniaNCT00690235 · started Nov 2007	Phase 4	Completed	33	University of Texas Southwestern Medical Center	Posted
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass SurgeryNCT01841359 · started Feb 2010	Phase 4	Completed	22	Joslin Diabetes Center	Posted
Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes MellitusNCT00442767 · started Feb 2007	Phase 4	Completed	8	Montefiore Medical Center	Posted
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsNCT00673387 · started Apr 2008	Phase 2	Completed	636	AstraZeneca	Posted
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinNCT00819234 · started Nov 2008	Phase 2	Completed	274	AstraZeneca	Posted
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsNCT01235741 · started Jan 2011	Phase 2	Terminated	213	AstraZeneca	Posted

47 further studies are registered. Participant counts marked * are the sponsor's estimate, not a final enrolment. Source: ClinicalTrials.gov, read directly from the registry and refreshed weekly.

What it is

Human amylin clumps into insoluble fibrils — the deposits found in the pancreas in type 2 diabetes — so it cannot be given as a drug. Pramlintide swaps three amino acids for proline, borrowing from rat amylin, to make a soluble version. Amylin Pharmaceuticals brought it to market as Symlin in 2005.

Its commercial life was short: three mealtime injections a day, a hypoglycaemia warning, and then the GLP-1 drugs. Its scientific legacy is the amylin pathway itself — cagrilintide is a weekly version of the same idea, and amycretin puts amylin and GLP-1 activity in one molecule.

How it is thought to work

Amylin is co-secreted with insulin and slows gastric emptying, suppresses glucagon after meals and signals satiety through the brainstem. Pramlintide replaces the amylin that is lost with beta cells in type 1 diabetes and deficient in advanced type 2, and the same satiety signal produces the modest weight loss seen in obesity.

What is still unknown

Whether a long-acting amylin analogue on its own can match GLP-1 drugs — cagrilintide's monotherapy data suggests not quite.
Why the EU application was withdrawn; no European trial programme was completed.

The molecule and how long it lasts

Identity

Formula: C171H267N51O53S2
Molecular weight: 3949 g/mol
CAS number: 151126-32-8
PubChem: CID 70691388

PubChem record, read 23 September 2026.

Pharmacokinetics

Route: Subcutaneous injection, before each major meal
Half-life: About 48 minutes
Licensed regimen (Symlin): Type 1: 15 mcg before major meals, increased in 15 mcg steps to 30 or 60 mcg; Type 2: 60 mcg before major meals, increased to 120 mcg

From the approved product's prescribing information: Symlin prescribing information (DailyMed) The regimen is the label's own wording, reproduced as a regulatory fact.

Regulatory status

European Union

Not authorised

A marketing application was withdrawn; no EU approval.

United States

Approved, prescription-only

FDA-approved 2005 (Symlin) for type 1 and type 2 diabetes using mealtime insulin. Boxed warning for insulin-induced severe hypoglycaemia.

United Kingdom

Unlicensed medicine

No MHRA licence.

Australia

Not registered

Not on the ARTG.

Canada

Not authorised

No Health Canada authorisation.

Sport (WADA)

Not prohibited

Not on the Prohibited List.

Questions people actually ask

Is pramlintide a weight-loss drug?

It causes modest weight loss — about 6–7 kg placebo-corrected over a year in its one obesity trial — but was never approved for that use and is far weaker than GLP-1 drugs. Its descendant cagrilintide, combined with semaglutide, is the modern version.

Why is it only approved in the US?

The European application was withdrawn and it was never pursued elsewhere. Three daily injections and a hypoglycaemia warning made it a niche product even in the US.

How does it relate to cagrilintide?

Same target — the amylin receptor — but pramlintide lasts hours and needs dosing with each meal, while cagrilintide is engineered to last a week. Pramlintide proved the mechanism; cagrilintide made it practical.

One page per claimed effect

ADoes Pramlintide help with blood glucose?Approval programme (type 1 and type 2)
BDoes Pramlintide help with body weight?1 RCT (n=411) with 8-month extension
ADoes Pramlintide help with body weight?Approval programme
AHow common is adverse effects with Pramlintide?Same trials

References

1
Smith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.Diabetes Care, 2008411 obese adults without diabetes; 4-month RCT plus 8-month extension.
2
Pramlintide acetate (Symlin) prescribing information.FDALicensed indications, glucose and weight data, boxed warning.

Change log

2026-09-10Initial publication. Grade A for the licensed diabetes use; B for obesity on a single trial.